Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee

Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…

Read More »

Biomoda Readies Products To Assist Insurer Reimbursement

Outsourcing Partner Speeds Entry Into Commercial Cancer Detection and Treatment Market Albuquerque, N.M. — (Business Wire), June 30, 2004 — Biomoda, Inc. announced today that it has contracted with reimbursement consulting firm, JR Associates, to help advance Biomoda’s patented biopharmaceutical products. Primarily, JR Associates consultants will investigate the potential for securing positive coverage, coding, and payment by Medicare and commercial…

Read More »